SeaStar Medical's CMO highlights QUELIMMUNE therapy for pediatric acute kidney injury in an upcoming oral presentation at a medical symposium.
SeaStar Medical announced its Chief Medical Officer will present at a pediatric symposium, a routine promotional event with no material financial impact.
SeaStar Medical Holding Corporation announced that its Chief Medical Officer will deliver an oral presentation on QUELIMMUNE. The session focuses on the company's extracorporeal therapy designed for critically ill pediatric patients suffering from acute kidney injury.
The presentation will highlight QUELIMMUNE, an extracorporeal therapy developed for critically ill pediatric patients experiencing acute kidney injury.